Gilead Surges After WHO Comments on Coronavirus Drug Testing
Comment of the Day

February 24 2020

Commentary by Eoin Treacy

Gilead Surges After WHO Comments on Coronavirus Drug Testing

This article by Drew Armstrong and Bailey Lipschultz for Bloomberg may be of interest to subscribers. Here is a section:

Remdesivir is the “one drug right now that we think may have efficacy,” Bruce Aylward, an assistant director-general at the World Health Organization, said at a briefing in Beijing. WHO officials and international scientists are in the country assessing the outbreak.

Eoin Treacy's view

The spread of the coronavirus accelerated internationally over the weekend with exponential growth in South Korea and Italy. Right now, there are no cures for the ailment and therefore any whiff of a successful treatment is likely to be rewarded with investor interest.

The share completed a yearlong range three weeks ago on news Gilead was giving China the right to start manufacturing it domestically. A sustained move below $65 would be required to question near-term scope for continued upside.

Back to top

You need to be logged in to comment.

New members registration